GCP
XERS icon

GSA Capital Partners’s Xeris Biopharma Holdings XERS Stock Holding History

GSA Capital Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$656K Sell
82,830
-18,608
-18% -$119K 0.04% 821
2026
Q1 		$588K Buy
101,438
+66,773
+193% +$443K 0.04% 812
2025
Q4 		$272K Sell
34,665
-34,051
-50% -$268K 0.02% 1225
2025
Q3 		$559K Buy
68,716
+6,394
+10% +$42.5K 0.05% 771
2025
Q2 		$291K Sell
62,322
-76,413
-55% -$350K 0.02% 1271
2025
Q1 		$762K Buy
138,735
+88,892
+178% +$359K 0.07% 516
2024
Q4 		$169K Buy
49,843
+22,493
+82% +$72.4K 0.01% 1453
2024
Q3 		$78K Sell
27,350
-578,313
-95% -$1.49M 0.01% 1506
2024
Q2 		$1.36M Buy
605,663
+593,952
+5,072% +$1.2M 0.1% 314
2024
Q1 		$26K Sell
11,711
-404,556
-97% -$1.05M ﹤0.01% 1550
2023
Q4 		$978K Buy
416,267
+35,036
+9% +$64.7K 0.08% 409
2023
Q3 		$709K Buy
381,231
+348,016
+1,048% +$797K 0.06% 585
2023
Q2 		$87K Sell
33,215
-282,810
-89% -$720K 0.01% 1385
2023
Q1 		$515K Buy
+316,025
New +$396K 0.05% 694
2022
Q4 		– Sell
-50,094
Closed -$78K – 1946
2022
Q3 		$78K Buy
50,094
+5,458
+12% +$9.03K 0.01% 1389
2022
Q2 		$69K Sell
44,636
-72,671
-62% -$153K 0.01% 1262
2022
Q1 		$300K Buy
117,307
+6,035
+5% +$14.7K 0.04% 893
2021
Q4 		$326K Buy
+111,272
New +$240K 0.04% 876
2021
Q3 		– Sell
-173,318
Closed -$705K – 1821
2021
Q2 		$705K Buy
173,318
+85,121
+97% +$325K 0.08% 416
2021
Q1 		$398K Buy
+88,197
New +$476K 0.07% 475
2020
Q2 		– Sell
-69,800
Closed -$136K – 1169
2020
Q1 		$136K Buy
69,800
+22,222
+47% +$95.6K 0.03% 844
2019
Q4 		$335K Buy
+47,578
New +$393K 0.04% 940

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

GSA Capital Partners's XERS Position: Q2 2026 in Review

GSA Capital Partners reduced its Xeris Biopharma Holdings (XERS) stake by 18% in Q2 2026, selling an estimated $119K and leaving 82,830 shares worth $656K. The position accounts for 0.04% of the portfolio, ranked #821.

GSA Capital Partners first reported a position in XERS in Q4 2019 and has held it in 22 quarters since. The position peaked at $1.36M in Q2 2024. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • GSA Capital Partners held 82,830 shares of Xeris Biopharma Holdings worth $656K as of Q2 2026.
  • GSA Capital Partners sold 18,608 Xeris Biopharma Holdings shares in Q2 2026, an estimated $119K.
  • Xeris Biopharma Holdings made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #821 holding.
  • GSA Capital Partners first reported a position in Xeris Biopharma Holdings in Q4 2019 and has held it in 22 quarters since.
  • GSA Capital Partners's Xeris Biopharma Holdings position peaked at $1.36M in Q2 2024.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.